(Q58229257)

English

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

prostate cancer

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

David R. H. Christie

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Allison Steigler

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Chantelle Wilcox

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

David S Lamb

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

David Joseph

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Chris Atkinson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

John Matthews

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Keen-Hun Tai

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Nigel A Spry

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Paul S Gleeson

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Catherine D'Este

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Trans-Tasman Radiation Oncology Group 96.01 Trialists

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

15 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1058-1068

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the proportion of treatment effect explained by a surrogate marker.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Proportion of treatment effect (PTE) explained by a surrogate marker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Critical analysis of prostate-specific antigen doubling time calculation methodology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970236-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(08)70236-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18929505%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58229257&oldid=1856150282"